Cargando…

Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion

Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cehofski, Lasse Jørgensen, Kruse, Anders, Mæng, Mads Odgaard, Kjaergaard, Benedict, Grauslund, Jakob, Honoré, Bent, Vorum, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672637/
https://www.ncbi.nlm.nih.gov/pubmed/38003895
http://dx.doi.org/10.3390/jpm13111580
_version_ 1785140438068363264
author Cehofski, Lasse Jørgensen
Kruse, Anders
Mæng, Mads Odgaard
Kjaergaard, Benedict
Grauslund, Jakob
Honoré, Bent
Vorum, Henrik
author_facet Cehofski, Lasse Jørgensen
Kruse, Anders
Mæng, Mads Odgaard
Kjaergaard, Benedict
Grauslund, Jakob
Honoré, Bent
Vorum, Henrik
author_sort Cehofski, Lasse Jørgensen
collection PubMed
description Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pigs, experimental CRVO was induced in both eyes with argon laser. The right eyes received an intravitreal injection of 0.05 mL bevacizumab (n = 9), while the left control eyes received 0.05 mL saline water (NaCl). Retinal samples were collected 15 days after induced CRVO. Label-free quantification nano-liquid chromatography–tandem mass spectrometry identified 59 proteins that were regulated following bevacizumab treatment. Following bevacizumab intervention, altered levels of bevacizumab components, including the Ig gamma-1 chain C region and the Ig kappa chain C region, were observed. Changes in other significantly regulated proteins ranged between 0.58–1.73, including for the NADH-ubiquinone oxidoreductase chain (fold change = 1.73), protein-transport protein Sec24B (fold change = 1.71), glycerol kinase (fold change = 1.61), guanine-nucleotide-binding protein G(T) subunit-gamma-T1 (fold change = 0.67), and prefoldin subunit 6 (fold change = 0.58). A high retinal concentration of bevacizumab was achieved within 15 days. Changes in the additional proteins were limited, suggesting a narrow mechanism of action.
format Online
Article
Text
id pubmed-10672637
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106726372023-11-07 Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion Cehofski, Lasse Jørgensen Kruse, Anders Mæng, Mads Odgaard Kjaergaard, Benedict Grauslund, Jakob Honoré, Bent Vorum, Henrik J Pers Med Article Bevacizumab is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the management of macular edema in central retinal vein occlusion (CRVO). Studying retinal protein changes in bevacizumab intervention may provide insights into mechanisms of action. In nine Danish Landrace pigs, experimental CRVO was induced in both eyes with argon laser. The right eyes received an intravitreal injection of 0.05 mL bevacizumab (n = 9), while the left control eyes received 0.05 mL saline water (NaCl). Retinal samples were collected 15 days after induced CRVO. Label-free quantification nano-liquid chromatography–tandem mass spectrometry identified 59 proteins that were regulated following bevacizumab treatment. Following bevacizumab intervention, altered levels of bevacizumab components, including the Ig gamma-1 chain C region and the Ig kappa chain C region, were observed. Changes in other significantly regulated proteins ranged between 0.58–1.73, including for the NADH-ubiquinone oxidoreductase chain (fold change = 1.73), protein-transport protein Sec24B (fold change = 1.71), glycerol kinase (fold change = 1.61), guanine-nucleotide-binding protein G(T) subunit-gamma-T1 (fold change = 0.67), and prefoldin subunit 6 (fold change = 0.58). A high retinal concentration of bevacizumab was achieved within 15 days. Changes in the additional proteins were limited, suggesting a narrow mechanism of action. MDPI 2023-11-07 /pmc/articles/PMC10672637/ /pubmed/38003895 http://dx.doi.org/10.3390/jpm13111580 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cehofski, Lasse Jørgensen
Kruse, Anders
Mæng, Mads Odgaard
Kjaergaard, Benedict
Grauslund, Jakob
Honoré, Bent
Vorum, Henrik
Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
title Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
title_full Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
title_fullStr Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
title_full_unstemmed Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
title_short Proteome Analysis of Bevacizumab Intervention in Experimental Central Retinal Vein Occlusion
title_sort proteome analysis of bevacizumab intervention in experimental central retinal vein occlusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672637/
https://www.ncbi.nlm.nih.gov/pubmed/38003895
http://dx.doi.org/10.3390/jpm13111580
work_keys_str_mv AT cehofskilassejørgensen proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion
AT kruseanders proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion
AT mængmadsodgaard proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion
AT kjaergaardbenedict proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion
AT grauslundjakob proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion
AT honorebent proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion
AT vorumhenrik proteomeanalysisofbevacizumabinterventioninexperimentalcentralretinalveinocclusion